| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1026650156 |
| P356 | DOI | 10.1038/ONC.2015.462 |
| P698 | PubMed publication ID | 26616857 |
| P2093 | author name string | V Asnafi | |
| E Macintyre | |||
| A Trinquand | |||
| M Tesio | |||
| P2860 | cites work | The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region | Q22010498 |
| Phosphorylation of the PTEN tail regulates protein stability and function | Q22254305 | ||
| Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia | Q24310753 | ||
| Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN | Q24322051 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia | Q24596097 | ||
| Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs | Q24629589 | ||
| A coding-independent function of gene and pseudogene mRNAs regulates tumour biology | Q24632651 | ||
| Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association | Q27620298 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate | Q28186818 | ||
| PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism | Q28238905 | ||
| A secreted PTEN phosphatase that enters cells to alter signaling and survival | Q28292188 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia | Q29614269 | ||
| Inducible gene targeting in mice | Q29614544 | ||
| Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 | ||
| Haematopoietic stem cells require a highly regulated protein synthesis rate | Q33588717 | ||
| Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. | Q33677433 | ||
| Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation | Q33732463 | ||
| Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus | Q33952806 | ||
| Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E | Q33980041 | ||
| PTEN action in leukaemia dictated by the tissue microenvironment | Q34196262 | ||
| A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells | Q34329463 | ||
| Suppression of leukemia development caused by PTEN loss | Q34533833 | ||
| Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency | Q34572866 | ||
| Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia | Q34645214 | ||
| Subtle variations in Pten dose determine cancer susceptibility | Q35055350 | ||
| Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer | Q35070165 | ||
| Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse | Q35102275 | ||
| Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice | Q35613150 | ||
| The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia | Q36216246 | ||
| T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus | Q46876173 | ||
| High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response | Q47906058 | ||
| Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor | Q49086388 | ||
| Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. | Q53084991 | ||
| FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. | Q54282770 | ||
| In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features. | Q54318657 | ||
| T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance | Q57185252 | ||
| High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice | Q57272679 | ||
| High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice | Q58378937 | ||
| Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations | Q58481776 | ||
| PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 | ||
| Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia | Q61774820 | ||
| Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia | Q62128235 | ||
| PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events | Q63865765 | ||
| Impaired Fas response and autoimmunity in Pten+/- mice | Q73019160 | ||
| Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN | Q73708485 | ||
| Acute lymphoblastic leukemia | Q79891876 | ||
| PTEN and p27 expression in mature T-cell and NK-cell neoplasms | Q81286052 | ||
| Comprehensive analysis of PTEN status in Sezary syndrome | Q85998575 | ||
| Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression | Q36248716 | ||
| Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. | Q36301565 | ||
| The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling | Q36403817 | ||
| Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial | Q36442504 | ||
| Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice | Q36883044 | ||
| NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia | Q36892602 | ||
| Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia | Q37009642 | ||
| The nuclear affairs of PTEN. | Q37063858 | ||
| Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia | Q37138122 | ||
| Molecular pathogenesis of T-cell leukaemia and lymphoma | Q37141761 | ||
| Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization | Q37246521 | ||
| High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia | Q37268926 | ||
| Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers | Q37272977 | ||
| β-Catenin induces T-cell transformation by promoting genomic instability | Q37474987 | ||
| c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation | Q37620912 | ||
| Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers | Q37627634 | ||
| The molecular basis of T cell acute lymphoblastic leukemia | Q38047834 | ||
| Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation | Q38837976 | ||
| Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice | Q39206146 | ||
| Targeting nonclassical oncogenes for therapy in T-ALL. | Q39362097 | ||
| AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. | Q39463725 | ||
| PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability | Q39933367 | ||
| Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors | Q40108131 | ||
| A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth | Q40184782 | ||
| PTEN functions by recruitment to cytoplasmic vesicles | Q40404987 | ||
| Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein | Q40421181 | ||
| Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. | Q40587498 | ||
| The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif | Q40601438 | ||
| mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. | Q41290971 | ||
| mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis | Q41910369 | ||
| Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction | Q42194172 | ||
| Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma. | Q42206056 | ||
| Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes | Q42594325 | ||
| Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice | Q42737245 | ||
| Suppression of T-cell lymphomagenesis in mice requires PTEN phosphatase activity. | Q43065543 | ||
| Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified. | Q43103123 | ||
| In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. | Q45187154 | ||
| Genetic background controls tumor development in PTEN-deficient mice. | Q46241404 | ||
| The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism | Q46666883 | ||
| A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice | Q46721107 | ||
| Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice | Q46768791 | ||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase | Q7187457 |
| P304 | page(s) | 3887-3896 | |
| P577 | publication date | 2015-11-30 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Oncogenic PTEN functions and models in T-cell malignancies | |
| P478 | volume | 35 |
| Q43122873 | A Mechanical Sensor Designed for Dynamic Joint Angle Measurement. |
| Q48106276 | Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia. |
| Q90288069 | Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance |
| Q91591537 | Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia |
| Q55216431 | Effects of CB2 and TRPV1 receptors' stimulation in pediatric acute T-lymphoblastic leukemia. |
| Q39137312 | Mechanisms for nonmitotic activation of Aurora-A at cilia. |
| Q47690412 | Modulation of PI3K/PTEN Pathway Does Not Affect Catalytic Activity of PDK1 in Jurkat Cells. |
| Q47629742 | Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN. |
| Q91826180 | The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response |
| Q92665751 | The role of aurora A and polo-like kinases in high-risk lymphomas |
| Q56378380 | Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update |
Search more.